Results 11 to 20 of about 67,507 (290)

Castrate-resistant prostate cancer [PDF]

Current Opinion in Urology, 2013
Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate-resistant prostate cancer (CRPC). In the past 3 years, several therapeutic agents have demonstrated survival improvements for CRPC after the receipt of prior docetaxel, leading to multiple approvals by the US Food and Drug Administration.The development of ...
Song, Zhao, Evan Y, Yu
openaire   +2 more sources

Nonmetastatic Castration-Resistant Prostate Cancer [PDF]

Korean Journal of Urology, 2014
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation.
Hong, Jun Hyuk, Kim, Isaac Y.
openaire   +2 more sources

Diethylstilbestrol in castration‐resistant prostate cancer [PDF]

BJU International, 2012
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Diethylstilbestrol (DES) was the first hormone treatment used for prostate cancer and has also ...
Wilkins, A, Shahidi, M, Parker, C, Gunapala, R, Thomas, K, Huddart, R, Horwich, A, Dearnaley, D   +7 more
openaire   +6 more sources

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +1 more source

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. [PDF]

PLoS ONE, 2013
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide ...
Steven Kregel, Kyle J Kiriluk, Alex M Rosen, Yi Cai, Edwin E Reyes, Kristen B Otto, Westin Tom, Gladell P Paner, Russell Z Szmulewitz, Donald J Vander Griend   +9 more
doaj   +1 more source

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Frontiers in Oncology, 2023
Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant.
Diana V. Maslov, Quinne Sember, Jason Cham, Munveer Bhangoo   +3 more
doaj   +1 more source

Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience [PDF]

, 2015
To describe our 10-year experience with the use of oral ethinylestradiol in the treatment of metastatic castration-resistant prostate cancer. METHODS: From February 2000 to April 2010, 116 patients with a metastatic castration-resistant prostate cancer
Aggarwal, Beer, Bonkhoff, Bono, Chadha, Corey, Di Silverio, Gasent Blesa, Izumi, Kitahara, Limonta, Montgomery, Shamash, Stein, Takezawa, Tannock, Wilkins   +16 more
core   +1 more source

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

Frontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai, Xianfu Cai, Chenguang Ding, Yang Li, Jin Zheng, Wujun Xue   +5 more
doaj   +1 more source